AUTHORS
Shivapriya Somasundaram, MS, Lakshmanan Krishnamurti, Professor Pediatrics,2
AFFILIATIONS
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
ABSTRACT
BACKGROUND
In an analysis of CIBMTR and EBMT data of patients undergoing hematopoietic cell transplantation (HCT) for sickle cell disease (SCD) from HLA-identical sibling donors (MSD) from 1986-2013, Gluckman et al in 2017 reported that event-free survival was higher in patients undergoing HCT performed after 2006, possibly because of improving supportive care. Similarly, case series and clinical trials have shown improved EFS following HCT from a haploidentical related donor in the modern era. The contemporary outcomes of allogeneic HCT have gained added significance for informed shared decision-making with the FDA approval of gene therapy and its recent extension to children as young as 2 years.
OBJECTIVES:
In this study, we sought to examine the trajectory of HCT outcomes for SCD in the modern era between 2008 and 2023.
METHODS:
We analyzed the HCT for SCD dataset obtained from BioLiNCC, which is based on data submitted to the Center for International Blood and Marrow Transplant Research (CIBMTR). We performed 1-year, 2-year, and 5-year Kaplan-Meier analyses for Event-Free Survival (EFS) and Overall Survival (OS) and compared the rates of Death, Graft Failure, Acute Graft versus Host Disease (AGVHD), and Chronic Graft versus Host Disease (CGVHD) between those who underwent transplant in 2008– 2017 and 2018 – 2023. The outcomes were compared between the 2 transplant eras separately for those with an HLA-matched sibling donor and those with a Haploidentical Donor. The outcome rates across the eras for each donor type were compared using chi-square or Fisher’s exact test, as required. A two-sided p-value <0.05 was considered statistically significant. All statistical analyses were performed using R (version 4.5.1; R Core Team, 2025).
RESULTS:
A total of 2026 patients underwent HCT for SCD from 1991 – 2023. We evaluated the 1763 patients who underwent HCT for SCD from 2008–2023, with a median year of HCT of 2018. Of a total of 989 HLA-matched Sibling Donor Recipients (MSD), 530 were from 2008–2017, and 459 were from 2018-2023. The median age of transplant for MSD was 10 years (0.9- 58) and 17 years (1- 52) for the haploidentical cohort. The event-free survival rates at 1-year (91.5% to 90.8%), 2-year (85.8% to 88.6%), and 5-year (83.2% to 85.8%) were not statistically significant (p=0.49) in the MSD cohort. While no major improvements were observed in the Overall Survival rates in the last 8 years (97.9% to 97.6 % for 1-year, 95.8% to 96.1% for 2-year and 95.1% to 93.9% for 5-year) for MSD cohort as well, with p = 0.94. The change in death rates in the MSD cohort (4.9% to 3.5%, p = 0.2695) was not statistically significant, while changes in Graft failure (12.7% to 8.4%, p = 0.0297), AGVHD (14.4% to 11.3%, p=0.0255), and CGVHD (21% to 14.8%, p = 0.012) were statistically significant.
Among Haploidentical donor recipients, 122 underwent HCT from 2008-2017, and 317 underwent HCT from 2018-2023. In haploidentical donor HCT, the overall survival rates remain stable (93.4% to 94.7% for 1-year, 90.7% to 92.5% for 2-year, and 88.8% to 89.3% for 5-year), with p=0.78. Improvement was observed in the EFS rates in the haploidentical cohort with 1-year (75.1% to 78%), 2-year (62.8% to 74.6%), and 5-year (56.8% to 70.8%), which was found to be statistically significant (p=0.046). A statistically significant decline was observed in the rates of death (16.4% to 7.3%, p = 0.0039) and graft failure rates (33.9% to 20.1%, p = 0.0027). AGVHD rates increased significantly (16.5% to 23.1%, p = 0.0384), while no statistically significant differences were observed for CGVHD (20.7% to 20.5%, p = 0.962).
CONCLUSION
EFS following HCT for SCD from haploidentical donors has significantly improved, with improvement in both death and graft failure rates, an increase in AGVHD, and stable rates of CGVHD. However, EFS following MSD HCT in the modern era remains stable, while rates of graft failure, AGVHD, and GVHD have improved. Improvements in haploidentical HCT outcomes may particularly reflect improvements in conditioning regimens, GVHD prophylaxis, and supportive care. These data on the continued improvement in HCT outcomes in the modern era have implications for patient and stakeholder education and informed shared decision-making.
DISCLOSURES
Shivapriya Somasundaram, MS: No relevant conflicts of interest to declare.